A new approach to quickly quantify antibodies and viral vectors in complex samples; Redox Electrochemical Detection offers high sensitivity and specificity. See how the simplicity of analysis using the automated Amperia RED system could empower your team with the at-line titre data you need to make confident, agile process optimisation decisions. Learn more https://lnkd.in/eyEa2ahn #bioprocessing #drugdevelopment
Abselion
Biotechnology Research
Cambridge, England 2,013 followers
Protein research made simple
About us
Our mission at Abselion is to simplify protein quantification for the scientists making crucial decisions to accelerate the development of biotherapeutics. Our tools help researchers to develop the medicine of the future and to find the best ways to produce new biomolecules. We focus on convenient tools with high degree of automation and low hands-on time to accelerate access to actionable data. Our award-winning Amperia system, built on proprietary Redox Electrochemical Detection (RED) technology, brings a new approach to biologics and viral-vector quantification for confident and cost-effective automated, at-line titre measurement, at any bench or bioreactor. By enabling agile and straightforward access to titre data, we empower scientists to focus on the decisions that can drive bioprocess optimisation and innovation. We are a dynamic, interdisciplinary team working at the intersection of biology, nanotechnology and data science. We value a flat hierarchy, where everyone is encouraged to share their ideas and to follow their passion.
- Website
-
www.abselion.com
External link for Abselion
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- Cambridge, England
- Type
- Privately Held
Locations
-
Primary
93 Lawrence Weaver Road
Cambridge, England CB3 0LE, GB
Employees at Abselion
Updates
-
Great discussions on technology driving progress in CGT development and manufacturing at #ELRIGDD24. Interested in a new approach to simple, rapid AAV quantification? Come and see us at booth BZ12. #genetherapy, #celltherapy, #bioprocessing, #drugdevelopment #biomanufacturing
-
Despite the immense potential of cell and gene therapies, widespread adoption is hindered by manufacturing limitations. Low yields, poor scalability, high costs, and quality testing challenges: unlocking the potential requires a paradigm shift in approach. We are delighted to be part of this collaborative project, and looking forward to discussing cutting-edge strategies and technological advancements that are driving progress in CGT development and manufacturing at #ELRIGDD24 this week. Come and see us at booth BZ12. #genetherapy, #celltherapy, #bioprocessing, #drugdevelopment #biomanufacturing
International consortium aims to revolutionise viral vector manufacturing A groundbreaking #collaboration between leading #biotechnology companies and #research organisations in the UK and Canada has secured £1.1 million in #funding to develop a next-generation #cell #platform for viral #vector production. Read more https://lnkd.in/efazghMx
-
Looking forward to exhibiting at ELRIG UK Drug Discovery 2024 next week! You can find us in the Breakthrough Zone at Booth BZ12. We will be showing Amperia, the automated all-in one benchtop solution for quantification of antibodies, AAVs and other molecules directly from crude samples. We look forward to engaging with the scientific community, sharing our insights, and showcasing Amperia. See you there! #bioprocessing #elrig #elrigdd24
-
We're growing, and we're looking for talented individuals to join our team in Cambridge, UK as we embark on our next phase. If you're passionate about revolutionizing protein analytics, check out these two opportunities! Research Associate: Develop and optimize assays for our cutting-edge analytical platform, Amperia. Collaborate with a multidisciplinary team to advance protein analysis. Sales Associate: Identify and acquire new customers for Amperia. Execute inside sales campaigns, attend trade shows, and contribute to our growth in the UK biotech market. We offer a dynamic, fast-paced work environment where you can make a real impact. Plus, you'll be working with a fantastic team and cutting-edge technology. Interested? Apply today! Research Associate (Job ID 3278): https://lnkd.in/ejuVhMCj Sales Associate (Job ID 3876): https://lnkd.in/efdYpjhB #hiring #biotech #lifesciences #cambridgejobs #research #sales
-
We are pleased to announce the appointment of Anne Jones to the Abselion Board as a Non-Executive Director. Anne brings over 25 years of global commercial experience in the Life Sciences, Healthcare, and Cell Therapy sectors, working with world-class corporations to drive business strategy and operational excellence. Anne is currently the President and CEO of G-CON, and has held leadership roles at Celularity, Genuity Science, Danaher Corporation, Agilent Technologies, and GE Healthcare. For the full announcement, please visit our website: https://lnkd.in/e5hyHaYe
-
Can multi-omics analysis, combined with innovative manufacturing and monitoring with on-line process analytics, reimagine the existing viral vector production process? We are delighted to be joining a collaborative project team that believes this new approach can develop the next-generation cell platform and unlock unprecedented viral vector production capabilities. Abselion will be applying our proprietary Redox-Electrochemical-Detection (RED) Technology and automated instrumentation to streamline and accelerate process analytics. “This project is the ultimate opportunity to showcase how process optimisation through at-line & on-line analytics can accelerate development and result in more efficient and robust production of the next generation of therapeutics.” Ruizhi Wang, CEO of Abselion. The project, jointly funded by Innovate UK and the National Research Council Canada / Conseil national de recherches Canada, is led by VVector Bio, and joined by the NRC and Revvity. Learn more: https://lnkd.in/eY6CrTej
-
How can we address the hurdles limiting scalable viral vector manufacturing for cell and gene therapy? A new international consortium has £1.1M funding for a fresh approach. Abselion is delighted to be joining VVector Bio, the National Research Council Canada / Conseil national de recherches Canada, and Revvity to apply a multifaceted strategy to unlock viral vector production capabilities. Jointly funded by Innovate UK and the NRC, as part of the Biomanufacturing of Biologics and Advanced Therapies programme, the project will combine detailed multi-omics analysis of the HEK-293 cell line with a new approach to manufacturing and process monitoring empowered by at-line and on-line process analytics. The project seeks to develop the next-generation cell platform for viral vector production, improving yields, quality, scalability and lowering costs, to ultimately help to accelerate the creation of therapies for patients. Learn more: https://lnkd.in/eY6CrTej #genetherapy, #celltherapy, #bioprocessing, #drugdevelopment #genomics
-
We are excited to share that Abselion is part of an international collaboration to develop the next-generation cell platform for viral vector production. Thanks to a £1.1 million grant from Innovate UK & National Research Council Canada / Conseil national de recherches Canada (NRC), the consortium, led by VVector Bio and involving the NRC, Revvity and Abselion, will apply a multifaceted strategy to revolutionize viral vector manufacturing. Congratulations to the project team: Alina Venereo-Sanchez, Aziza Manceur, Alan Fletcher, Ruizhi Wang. Learn more about the project: https://lnkd.in/eY6CrTej #genetherapy, #celltherapy, #bioprocessing, #drugdevelopment, #innovation
-
We're thrilled to announce the winner of our iPad raffle at #ESACT2024 -Drumroll, please! 🥁🥁🥁 Johanna Katharina Fritsche, PhD student at the University of Bayreuth in Germany! Johanna's groundbreaking research focuses on microplastics and their impact on human health. We're incredibly proud to support such a promising young scientist. Congratulations, Johanna! We can't wait to see the amazing discoveries you'll make! #ESACT2024 #Abselion